finance.yahoo.com ·
Wall Street Analysts Bullish Bio
Topic context
This topic has been covered 235639 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedBio-Techne's revenue decline reflects weaker biotech spending and delayed shipments, indicating a demand slowdown in life sciences tools and reagents. The company's margin is squeezed by lower volume and fixed cost absorption. The impact is single-company/supply-chain-specific, primarily affecting Bio-Techne and its suppliers/distributors in the life sciences sector. No direct winners/losers specified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Bio-Techne (TECH) market cap $7.5B, shares down 18% YTD vs S&P 500 +9.2%.
- Q3 2026 revenue $311.4M, down 2% YoY; adjusted EPS $0.53.
- Analysts project 1.2% EPS decline for FY ending June 2026.
- Consensus rating 'Moderate Buy' from 15 analysts; mean PT $63.75 (32.2% upside).
- Wells Fargo analyst Brandon Couillard sets PT $62.
Life sciences tools may see a 3-5% revenue decline over the next 2-4 weeks due to inventory destocking.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid
- PHARMA_BIOTECHmid
Related stories
newkerala.com
Indian Markets Open Flat Amid Cautious Sentiment Dii 998
sanantoniopost.com
Indian Markets Open Flat Amid Cautious Sentiment Dii Inflows Support Equities Despite Global Pressures
tickerreport.com
Financial Contrast 8x8 Nasdaqeght and Braze Nasdaqbrze
economictimes.indiatimes.com
US Stock Market Space Stocks Surge as Spacex IPO Buzz Fuels Investor Rally
hedgeco.net